Topical tacrolimus treatment does not facilitate photocarcinogenesis in cancer-prone mice

Shiga, Takeo; Yokogawa, Maki; Nakajima, Kimiko; Kitagawa, Chie; Tarutani, Masahito; Kumagai, Naoya; Sano, Shigetoshi

doi:10.1016/j.jdermsci.2012.08.005

Search citation statements

Order By: Relevance

Paper Sections

Select...

Skin Atrophy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Photocarcinogenicity studies did not display a shortened time until the manifestation of skin tumors in the mouse model [88] and measurements of UV-induced dipyrimidine dimers gave no evidence of increased epidermal DNA damage [89]. In contrast, a study in hairless mice had shown an increased formation of skin papillomas after topical tacrolimus, but not after topical pimecrolimus; its relevance to humans remains unclear [87].…”

Section: Skin Atrophymentioning

confidence: 99%

Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema

Prucha

Schnopp

Akdiş

et al. 2013

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Pimecrolimus represents a valuable part of active and proactive therapy in AE. That being said, the long-term safety of topical calcineurin inhibitors remains to be investigated. Given the results from experimental photocarcinogenicity studies, effective sun protection should be employed during the therapy, although an increased risk for skin malignancies and lymphomas was not found in recent studies. Pimecrolimus should be considered as an alternative therapeutic approach in AE treatment management going along with a corticoid-sparing effect.

show abstract

Section: Skin Atrophymentioning

confidence: 99%